期刊文献+

肺癌患者化疗前后凝血、纤溶功能及血小板参数的变化及其临床意义 被引量:12

The Changes of Coagulation,Fibrinolysis Function and Platelet Parameters of Patients with Lung Cancer and Their Clinical Significance
下载PDF
导出
摘要 目的研究肺癌患者化疗前后凝血、纤溶功能及血小板参数的变化及其临床意义。方法 56例肺癌患者肺癌患者化疗前后凝血、纤溶功能及血小板参数的变化被检测,并以56例健康体检者作为对照。结果肺癌患者血浆纤维蛋白原、血小板计数和血小板体积分布宽度分别为(4.31±0.75)g·L-1、(287.41±97.56)×109·L-1和16.01±2.86 fl,健康体检者分别为(3.19±0.46)g·L-1、(205.62±51.97)×109·L-1和(15.12±1.57)fl,比较差异均有统计学意义(P均<0.05)。化疗后肺癌患者凝血酶原时间由化疗前的(11.35±0.86)s减少为(10.21±0.65)s,血小板计数由(287.41±97.56)×109·L-1减少为(207.05±81.36)×109·L-1,血红蛋白由(125.79±31.08)g·L-1减少为(108.20±25.74)g·L-1,比较差异均有统计学意义(P均<0.05)。结论化疗可能导致肺癌患者的凝血、纤溶功能异常。 Objective To research the changes of coagulation,fibrinolysis function and platelet parameters of patients with lung cancer and their clinical significance. Methods The changes of coagulation,fibrinolysis function and platelet parameters of the 56 patients with lung cancer were detected before and after treatment,and those of the healthy volunteers were detected too. Results The fibrinogen,platelets and platelet distribution width of the patients with lung cancer were(4. 31 ± 0. 75)g·L^-1 ,(287. 41 ± 97. 56)× 10^9 ·L^-1 and(16. 01 ± 2. 86)fl;those of the healthy volunteers were(3.19±0.46)g·L^-1,(205.62 ±51.97)×10^9·L^-1 and(15.12 ±1.57)fl(P〈0. 05). After the chemotherapy,the prothrombin time of patients with lung cancer decreased from(11. 35 ± 0. 86)s to(10.21 ± 0. 65)s,the platelets decreased from(287. 41 ± 97. 56)× 10^9 ·L^-1 to(207. 05 ± 81. 36)× 10^9·L^-1,the hemoglobin decreased from(125.79 ±31.08)g·L^-1 to(108.20 ±25.74)g·L^-1(P〈0.05). Conclusion The chemotherapy can induce the changes of coagulation and fibrinolysis function of the patients with lung cancer.
出处 《肿瘤基础与临床》 2015年第2期150-153,共4页 journal of basic and clinical oncology
关键词 肺癌 化疗 凝血功能 纤溶功能 血小板参数 lung cancer chemotherapy coagulation function fibrinolysis function platelet parameters
  • 相关文献

参考文献8

二级参考文献68

共引文献56

同被引文献117

  • 1I-Iirsh V. Skeletal disease contributes substantially to morbidity and mortality in patients with lung cancer[ J]. Clin Lung Cancer, 2009, 10(4) : 223-229.
  • 2Tas F, Kilic L, Serilmez M, et al. Clinical and prognostic significance of coagulation assays in lung cancer[J]. Respir Med, 2013, 107 (3) : 451-457.
  • 3Lopez-Gomez MC. Gomez-Raposo C, Lobo Samper F. Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients[ J]. Cancer, 2008, 113 ( 1 ) : 223-224.
  • 4Voulgaris E, Pentheroudakis G, Vassou A, et al. Disseminated intravascular coagulation (DIC) and non-small cell lung cancer (NSCLC): report of a case and review of the literature [ J ]. Lung Cancer, 2009, 64(2) : 247-249.
  • 5Gay LJ, Felding-Habermann B. Contribution of platelets to tumour metastasis[Jl. Nat Rev Cancer, 2011, 11(2) : 123-134.
  • 6Pilatova K, Zdrazilova-Dubska L, Klement GL. The role of platelets in tumour growth [ J 1. Klin Onkol, 2012, 25 ( Suppl 2 ) : 2S50- 2557.
  • 7Labelle M, Begum S, Hynes RO. Direct signaling between platelets and cancer ceils induces an epithelial-mesenchymaMike transition and promotes metastasis [ J ]. Cancer Cell, 2011,20 (5) : 576-590.
  • 8Agnelli G, Gussoni G, Bianchini C, et al. Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy : a randomised, placebo-controlled, double-blind study [ J ]. Lancet Oncol, 2009, 10(10): 943-949.
  • 9Verso M, Gussoni G, Agnelli G. Prevention of venous thromboembolism in patients with advanced lung cancer receiving chemotherapy: a combined analysis of the PROTECHT and TOPIC-2 studies [ J ]. J Thromb Haemost, 2010, 8(7) : 1649-1651.
  • 10Pavey S J, Hawson GA, Marsh NA. Impact of the fibrinolytic enzyme system on prognosis and survival associated with non-small cell lung carcinoma[J]. Blood Coagul Fibrinolysis, 2001, 12( 1 ) : 51-58.

引证文献12

二级引证文献64

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部